PHT Corporation Grows 61% in 2014 as Pharmaceutical Industry Champions its Patient-Centric eCOA Systems for Clinical Research

PHT Corporation Grows 61% in 2014 as Pharmaceutical Industry Champions its Patient-Centric eCOA Systems for Clinical Research

Patient-driven eData innovator revenues up 43% year-over-year as pharma, biotech and life sciences organizations standardize on PHT electronic clinical outcome assessment (eCOA) systems

PRO & eCOA Congress 2015 January 21, 2015 09:00 AM Eastern Standard Time

BOSTON & GENEVA--()--The pharmaceutical industry continued its rapid adoption of the PHT Corporation patient-driven eData Patient Suite for clinical research in 2014. PHT achieved 61% growth in new business and 43% year-over-year revenue growth. PHT is the leading provider of mobile technologies used to collect patient and clinician reported outcomes in clinical research.

Over 31 pharmaceutical, biotech and life sciences companies chose the PHT electronic clinical outcome assessment (eCOA) System for 94 clinical trials and studies. PHT welcomed 8 new clients through direct sales and CRO partnerships.

PHT saw 31% growth in scientific consulting and education services and expanded the offering to include Rater Training based on customer demand. PHT now offers Rater Training for a variety of instruments including the C-SSRS, M.I.N.I and Sheehan-STS and SDS.

Customer achievements included Celgene, which used the PHT SitePad® System to collect eData for its FDA-approved Otezla® to treat adults with psoriasis and active psoriatic arthritis. Agile Therapeutics used the LogPad® System for the Phase III trial of the Twirla® contraceptive patch. Celgene's Senior Study manager talks about the Otezla trial:

Oncology, Immunology and Respiratory were the fastest growing therapeutic areas for PHT eCOA Systems, driving sales of the PHT SitePad System. More trials used combination offerings, especially the LogPad and SitePad Systems, to support increased trial complexity. More late-phase programs including registries and comparative effectiveness studies used the PHT NetPRO™ web system.

PHT President and CEO Philip Lee, said, "PHT and eCOA Systems are experiencing accelerated growth as the adoption of patient-driven eData increases dramatically. Sponsors are moving away from paper to eClinical systems for data collection and management throughout clinical research. PHT is driving adoption through flexible eCOA systems configured to support the scientific goals of individual trials, backed by an organization-wide focus on delivering a superior experience to sponsors, patients and sites."

Top 2014 Highlights

SmartReports™ – New project performance dashboards and interactive reports including patient views make trial management more convenient for sponsors, sites and patients. Watch a short video:

LogPad System on Google Nexus 5 Android Smartphone – The only ePRO diary available on this smartphone supports the BYOD model and offers scanning technology to automate patient enrollment and improve the accuracy of clinical research program medication and supply tracking.

eTMF Optimize™ – This offering supports faster drug submissions and improves clinical trial execution with rapid, regular population of the electronic trial master file.

Electronic Version of the Mini-International Neuropsychiatric Interview Questionnaire (M.I.N.I) for Global Clinical Trials – PHT co-developed and earned Preferred Provider status for licensing the electronic version of the M.I.N.I for clinical trials and research studies on the SitePad System and NetPRO™.

Industry Education

Patient Centric Video Series – The new series features scientists, technologists and a patient discussing the future of patient centric clinical research. Watch a 1-minute series preview:

International #PatientBYOD Day – PHT hosted this worldwide social media phenomenon in conjunction with the 10th Annual US PRO & eCOA Congress. Follow the conversation:

PRO & eCOA Congress – In Boston and Barcelona pharmaceutical industry trendsetters shared lessons learned, best practices and trends in leveraging PRO and eCOA Systems for better clinical research. Save the date for the 11th Annual PRO & eCOA Congress, 2-5 June in Lisbon:

PHT Vice President of Marketing and Corporate Strategy, Sheila Rocchio MBA, commented, "Customers chose the PHT eCOA System in 2014 because of the flexibility PHT offers with different data collection options, the expertise of the clinical science and consulting team, and the PHT focus on delivering operational excellence."

About PHT Corporation

PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. Visit for more information on PHT. Follow PHT on LinkedInFacebookTwitterGoogle+ and YouTube.


For PHT Corporation
Brenda Nashawaty, 617-688-3253
[email protected]


Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.